NIKKEI 225
39,726.39 +553.24 (+1.41%) HANG SENG
18,047.38 -25.52 (-0.14%) CRUDE OIL
81.18 +0.35 (+0.43%) GOLD FUTURES
2,331.60 +0.80 (+0.03%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,811.71 +486.15 (+1.01%)
VIR Mar 2025 2.500 call
| Previous close | 9.74 |
| Open | N/A |
| Bid | 6.40 |
| Ask | 8.00 |
| Strike | 2.50 |
| Expiry date | 2025-03-21 |
| Day's range | 9.74 - 9.74 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
Simply Wall St.Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
ZacksVir Biotechnology (VIR) Up on Positive Data From HDV Study
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
BenzingaWhy Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
On Wednesday, Vir Biotechnology Inc (NASDAQ:VIR) announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart and elebsiran for chronic hepatitis delta. Preliminary data from the Phase 2 trial show that treatment with tobevibart alone or combined with elebsiran was generally well tolerated. Participants achieved high virologic response rates at weeks 12 and 24, durable virologic response through 48 weeks, and high alanine transaminase (ALT) normal
